HomeUSAUmoja Biopharma Raises $100M in Series C Financing

Umoja Biopharma Raises $100M in Series C Financing

-

Umoja Biopharma

Umoja Biopharma, a Seattle, WA-based clinical-stage company which specializes in vivo cell therapies, raised $100M Series C financing.

The round was led by Double Point Ventures and DCVC Bio, with participation from new and existing investors including ARK Invest, Cormorant Asset Management, MPM Capital, Qiming Venture Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank Vision Fund 2, CaaS Capital, Emerson Collective Investments managed by Yosemite, K2 HealthVentures, Myeloma Investment Fund, University of Minnesota Endowment, and other prominent life science investors.

The company intends to use the funds to advance its in vivo CAR T cell therapy pipeline, including its lead CD22 UB-VV400 program in multiple oncology and autoimmune clinical studies.

Led by CEO Andrew Scharenberg, Umoja Biopharma is a clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity. Its VivoVec™ in vivo gene delivery technology empowers a patient’s own immune system to fight disease.

In conjunction with the Series C financing, Umoja added Campbell Murray, M.D., a Senior Adviser at Double Point Ventures, as a new Board member.

FinSMEs

20/01/2025

THE DAILY NEWSLETTER - SIGNUP